Insulet Corporation (PODD) PT Lowered to $330 at Bernstein

Bernstein SocGen Group analyst Lee Hambright lowered the price target on Insulet Corporation (NASDAQ: PODD) to $330.00 (from $380.00) while maintaining an Outperform rating.

The analyst commented: "Strong moat; ample runway for growth; Investors are concerned. The insulin pump space is getting more competitive as established players (TNDM, MDT) make progress on pipelines and newer entrants expand their commercial presence. Investors worry about competitive patch pumps and potential price pressure in the pharmacy channel. Recent Rx data has exacerbated these concerns, and PODD shares have underperformed.

We rate PODD Outperform with a price target of $330 (down from $380) using a P/S multiple of 6.0x (down from 7.0x to reflect conservatism and growing investor concerns re: the competitive environment for pumps) against our FY27 sales estimate of $3.91bn (up from $3.87bn), and we see upside to this valuation driven by T2D execution and margin expansion. Note this target equates to a P/E of 40x on our FY27 EPS of $8.25. For more, see our investor day recap, initiation report, and 3Q25 recap."

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASD
• Trupanion, Inc. (TRUP) PT Raised to $29 at Stifel as Pets Best Rolls Off Business
• Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates